Symbols / AEMD
AEMD Chart
About
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 2.58M |
| Enterprise Value | -3.96M | Income | -11.52M | Sales | — |
| Book/sh | 6.90 | Cash/sh | 5.29 | Dividend Yield | — |
| Payout | 0.00% | Employees | 9 | IPO | — |
| P/E | 0.01 | Forward P/E | -0.34 | PEG | — |
| P/S | — | P/B | 0.28 | P/C | — |
| EV/EBITDA | 0.56 | EV/Sales | — | Quick Ratio | 5.53 |
| Current Ratio | 5.68 | Debt/Eq | 6.22 | LT Debt/Eq | — |
| EPS (ttm) | 209.20 | EPS next Y | -5.70 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-12 | ROA | -62.88% |
| ROE | -208.60% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.32M |
| Shs Float | 1.31M | Short Float | 5.21% | Short Ratio | 0.71 |
| Short Interest | — | 52W High | 53.60 | 52W Low | 1.86 |
| Beta | 1.60 | Avg Volume | 124.33K | Volume | 39.85K |
| Target Price | $9.75 | Recom | Hold | Prev Close | $1.93 |
| Price | $1.96 | Change | 1.55% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.75
Mean price target
2. Current target
$2.14
Latest analyst target
3. DCF / Fair value
$-62.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.14
Low
$9.75
High
$9.75
Mean
$9.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-14 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2025-03-10 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-02-19 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-30 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-06-24 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-03-04 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-10-24 | main | HC Wainwright & Co. | Buy → Buy | $23 |
- Aethlon Medical (Nasdaq: AEMD) reports Hemopurifier resin binding Long COVID EVs and miRNAs - Stock Titan ue, 02 Dec 2025 08
- Aethlon Medical stock rises after Long COVID study supports Hemopurifier - Investing.com ue, 02 Dec 2025 08
- Maxim Group Maintains Aethlon Medical(AEMD.US) With Hold Rating - 富途牛牛 Sun, 15 Feb 2026 03
- Aethlon Medical Q3 2026 Earnings Call Transcript - MarketBeat hu, 12 Feb 2026 08
- Why Is Aethlon Medical Stock (AEMD) Up 60% Today? - TipRanks hu, 21 Aug 2025 07
- Why did Aethlon Medical stock tumble over 12% today? - MSN Mon, 08 Dec 2025 08
- Aethlon Medical announces pricing of $4.5M common stock, warrant offering - Yahoo Finance Fri, 05 Sep 2025 07
- Aethlon Medical (AEMD) Poised to Report Earnings with Consensus - GuruFocus hu, 26 Jun 2025 07
- Aethlon Medical’s Stock Surge Raises Eyebrows - StocksToTrade hu, 21 Aug 2025 07
- Aethlon Medical to Announce Q3 Earnings on February 11 - Intellectia AI Wed, 11 Feb 2026 23
- 12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga ue, 20 Jan 2026 08
- Aethlon Medical enacts 1-for-10 reverse stock split effective Thursday - Investing.com hu, 16 Oct 2025 07
- Morning Market Movers: PMAX, KXIN, ACHC, AEMD See Big Swings - RTTNews Wed, 03 Dec 2025 08
- Aethlon Medical Announces Reverse Stock Split - TipRanks hu, 16 Oct 2025 07
- Aethlon Medical (AEMD.US) is scheduled to release its earnings report after the market closes on February 12. - 富途牛牛 Sat, 07 Feb 2026 23
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 142857 | 50000 | — | Stock Award(Grant) at price 0.35 per share. | BROENNIMAN EDWARD G | Director | — | 2025-04-23 00:00:00 | D |
| 1 | 142857 | 50000 | — | Stock Award(Grant) at price 0.35 per share. | ROSSETTI ANGELA | Director | — | 2025-04-23 00:00:00 | D |
| 2 | 142857 | 51143 | — | Stock Award(Grant) at price 0.36 per share. | SHAH CHETAN S | Director | — | 2025-04-23 00:00:00 | D |
| 3 | 142857 | 50000 | — | Stock Award(Grant) at price 0.35 per share. | GIKAKIS NICOLAS | Director | — | 2025-04-23 00:00:00 | D |
| 4 | 32894 | 49999 | — | Stock Award(Grant) at price 1.52 per share. | BROENNIMAN EDWARD G | Director | — | 2024-04-16 00:00:00 | D |
| 5 | 32894 | 49999 | — | Stock Award(Grant) at price 1.52 per share. | ROSSETTI ANGELA | Director | — | 2024-04-16 00:00:00 | D |
| 6 | 32894 | 49999 | — | Stock Award(Grant) at price 1.52 per share. | SHAH CHETAN S | Director | — | 2024-04-16 00:00:00 | D |
| 7 | 32894 | 49999 | — | Stock Award(Grant) at price 1.52 per share. | GIKAKIS NICOLAS | Director | — | 2024-04-16 00:00:00 | D |
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -13.04M | -12.28M | -11.52M | -10.30M |
| TotalUnusualItems | 0.00 | -142.12K | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -142.12K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -13.39M | -12.21M | -12.03M | -10.42M |
| ReconciledDepreciation | 339.56K | 359.06K | 240.89K | 123.69K |
| EBITDA | -13.04M | -12.28M | -11.66M | -10.30M |
| EBIT | -13.38M | -12.64M | -11.90M | -10.42M |
| NetInterestIncome | 288.01K | 447.36K | 10.97K | 0.00 |
| InterestExpense | 10.11K | 1.58K | ||
| InterestIncome | 298.12K | 447.36K | 10.97K | 0.00 |
| NormalizedIncome | -13.39M | -12.21M | -11.89M | -10.42M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -13.39M | -12.21M | -12.03M | -10.42M |
| TotalExpenses | 9.34M | 12.64M | 12.47M | 10.72M |
| TotalOperatingIncomeAsReported | -9.34M | -12.64M | -11.90M | -10.42M |
| DilutedAverageShares | 1.56M | 314.10K | 256.72K | 184.46K |
| BasicAverageShares | 1.56M | 314.10K | 256.72K | 184.46K |
| DilutedEPS | -8.58 | -388.70 | -47.20 | -56.80 |
| BasicEPS | -8.58 | -388.70 | -47.20 | -56.80 |
| DilutedNIAvailtoComStockholders | -13.39M | -12.21M | -12.03M | -10.42M |
| NetIncomeCommonStockholders | -13.39M | -12.21M | -12.03M | -10.42M |
| NetIncome | -13.39M | -12.21M | -12.03M | -10.42M |
| MinorityInterests | 0.00 | 4.79K | 4.79K | |
| NetIncomeIncludingNoncontrollingInterests | -13.39M | -12.21M | -12.03M | -10.42M |
| NetIncomeContinuousOperations | -13.39M | -12.21M | -12.03M | -10.42M |
| PretaxIncome | -13.39M | -12.21M | -12.03M | -10.42M |
| OtherIncomeExpense | -4.33M | -18.96K | -142.12K | |
| OtherNonOperatingIncomeExpenses | -4.33M | -18.96K | ||
| SpecialIncomeCharges | 0.00 | -142.12K | 0.00 | 0.00 |
| GainOnSaleOfBusiness | 0.00 | -142.12K | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 288.01K | 447.36K | 10.97K | 0.00 |
| InterestExpenseNonOperating | 10.11K | 1.58K | ||
| InterestIncomeNonOperating | 298.12K | 447.36K | 10.97K | 0.00 |
| OperatingIncome | -9.34M | -12.64M | -11.90M | -10.42M |
| OperatingExpense | 9.34M | 12.64M | 12.47M | 10.72M |
| SellingGeneralAndAdministration | 9.34M | 12.64M | 12.47M | 10.72M |
| GeneralAndAdministrativeExpense | 9.34M | 12.64M | 12.47M | 10.72M |
| OtherGandA | 5.47M | 7.43M | 8.03M | 6.09M |
| SalariesAndWages | 3.87M | 5.21M | 4.44M | 4.63M |
| TotalRevenue | 0.00 | 0.00 | 574.25K | 294.17K |
| OperatingRevenue | 0.00 | 0.00 | 574.25K | 294.17K |
| Line Item | 2025-03-31 | 2024-03-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 574.50K | 0.00 | ||
| OrdinarySharesNumber | 2.01M | 328.71K | 287.40K | 192.74K |
| ShareIssued | 2.59M | 328.71K | 287.40K | 192.74K |
| TotalDebt | 649.75K | 940.32K | 1.21M | 729.41K |
| TangibleBookValue | 5.12M | 5.77M | 15.06M | 17.13M |
| InvestedCapital | 5.12M | 5.77M | 15.06M | 17.13M |
| WorkingCapital | 4.05M | 4.40M | 13.59M | 16.33M |
| NetTangibleAssets | 5.12M | 5.77M | 15.06M | 17.13M |
| CapitalLeaseObligations | 649.75K | 940.32K | 1.21M | 729.41K |
| CommonStockEquity | 5.12M | 5.77M | 15.06M | 17.13M |
| TotalCapitalization | 5.12M | 5.77M | 15.06M | 17.13M |
| TotalEquityGrossMinorityInterest | 5.12M | 5.77M | 15.06M | 16.99M |
| MinorityInterest | 0.00 | -141.71K | -136.91K | |
| StockholdersEquity | 5.12M | 5.77M | 15.06M | 17.13M |
| GainsLossesNotAffectingRetainedEarnings | -17.13K | -6.94K | -6.14K | |
| OtherEquityAdjustments | -17.13K | -6.94K | -6.14K | |
| RetainedEarnings | -167.95M | -154.57M | -142.36M | -130.33M |
| AdditionalPaidInCapital | 173.09M | 160.34M | 157.43M | 147.45M |
| CapitalStock | 2.59K | 329.00 | 2.30K | 15.42K |
| CommonStock | 2.59K | 329.00 | 2.30K | 15.42K |
| TotalLiabilitiesNetMinorityInterest | 2.24M | 2.48M | 2.44M | 2.43M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 336.72K | 649.75K | 939.64K | 602.50K |
| LongTermDebtAndCapitalLeaseObligation | 336.72K | 649.75K | 939.64K | 602.50K |
| LongTermCapitalLeaseObligation | 336.72K | 649.75K | 939.64K | 602.50K |
| CurrentLiabilities | 1.90M | 1.83M | 1.51M | 1.82M |
| OtherCurrentLiabilities | 178.21K | |||
| CurrentDeferredLiabilities | 0.00 | 344.55K | 114.85K | |
| CurrentDeferredRevenue | 0.00 | 344.55K | 114.85K | |
| CurrentDebtAndCapitalLeaseObligation | 313.03K | 290.56K | 269.39K | 126.91K |
| CurrentCapitalLeaseObligation | 313.03K | 290.56K | 269.39K | 126.91K |
| PayablesAndAccruedExpenses | 1.41M | 1.54M | 1.24M | 1.35M |
| CurrentAccruedExpenses | 873.52K | 761.47K | 802.81K | 852.63K |
| Payables | 534.52K | 777.86K | 432.89K | 499.96K |
| AccountsPayable | 534.52K | 777.86K | 432.89K | 499.96K |
| TotalAssets | 7.36M | 8.25M | 17.51M | 19.42M |
| TotalNonCurrentAssets | 1.41M | 2.02M | 2.42M | 1.26M |
| OtherNonCurrentAssets | 97.81K | 87.51K | 87.51K | 87.51K |
| NonCurrentPrepaidAssets | 33.30K | 33.30K | 33.30K | 33.30K |
| GoodwillAndOtherIntangibleAssets | 550.00 | 1.10K | 1.65K | 2.20K |
| OtherIntangibleAssets | 550.00 | 1.10K | 1.65K | 2.20K |
| NetPPE | 1.28M | 1.90M | 2.30M | 1.14M |
| AccumulatedDepreciation | -978.89K | -990.55K | -734.21K | -493.86K |
| GrossPPE | 2.26M | 2.89M | 3.03M | 1.63M |
| Leases | 893.13K | 893.13K | 888.22K | 121.69K |
| OtherProperties | 601.85K | 883.05K | 1.15M | |
| MachineryFurnitureEquipment | 761.98K | 1.11M | 989.99K | 813.41K |
| BuildingsAndImprovements | 1.15M | 696.70K | 40.36K | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 5.95M | 6.23M | 15.09M | 18.16M |
| OtherCurrentAssets | 448.54K | 505.98K | 557.62K | 956.62K |
| CurrentDeferredAssets | 0.00 | 277.83K | 0.00 | |
| PrepaidAssets | 956.62K | 341.08K | ||
| Receivables | 0.00 | 127.97K | 149.08K | |
| AccountsReceivable | 0.00 | 127.97K | 149.08K | |
| CashCashEquivalentsAndShortTermInvestments | 5.50M | 5.44M | 14.53M | 17.07M |
| CashAndCashEquivalents | 5.50M | 5.44M | 14.53M | 17.07M |
| CashEquivalents | 5.16M | 4.74M | 13.91M | |
| CashFinancial | 343.37K | 705.51K | 621.97K | 17.07M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.65M | -10.38M | -11.45M | -10.12M |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 3.54M | 1.32M | 8.93M | 17.46M |
| CapitalExpenditure | -250.87K | -943.11K | -349.19K | -59.88K |
| InterestPaidSupplementalData | 0.00 | |||
| EndCashPosition | 5.60M | 5.53M | 14.62M | 17.16M |
| BeginningCashPosition | 5.53M | 14.62M | 17.16M | 9.91M |
| EffectOfExchangeRateChanges | -12.26K | 2.11K | -5.96K | |
| ChangesInCash | 81.85K | -9.09M | -2.53M | 7.25M |
| FinancingCashFlow | 7.73M | 1.29M | 8.91M | 17.37M |
| CashFlowFromContinuingFinancingActivities | 7.73M | 1.29M | 8.91M | 17.37M |
| NetOtherFinancingCharges | -183.78K | -34.78K | -12.49K | -88.12K |
| ProceedsFromStockOptionExercised | 4.37M | 0.00 | ||
| NetCommonStockIssuance | 3.54M | 1.32M | 8.93M | 17.46M |
| CommonStockIssuance | 3.54M | 1.32M | 8.93M | 17.46M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtPayments | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| InvestingCashFlow | 0.00 | -250.87K | -943.11K | -349.19K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -250.87K | -943.11K | -349.19K |
| NetPPEPurchaseAndSale | 0.00 | -250.87K | -943.11K | -349.19K |
| PurchaseOfPPE | 0.00 | -250.87K | -943.11K | -349.19K |
| OperatingCashFlow | -7.65M | -10.13M | -10.51M | -9.77M |
| CashFlowFromContinuingOperatingActivities | -7.65M | -10.13M | -10.51M | -9.77M |
| ChangeInWorkingCapital | 93.69K | 478.66K | 65.34K | -251.11K |
| ChangeInOtherWorkingCapital | -344.55K | 229.70K | 14.85K | |
| ChangeInPayablesAndAccruedExpense | -20.23K | 488.89K | -116.25K | 134.76K |
| ChangeInPayable | -20.23K | 488.89K | -116.25K | 134.76K |
| ChangeInAccountPayable | -53.36K | 156.68K | -174.73K | 97.54K |
| ChangeInPrepaidAssets | 113.92K | -10.23K | 398.17K | -636.69K |
| ChangeInReceivables | 0.00 | 127.97K | 21.12K | 57.65K |
| ChangesInAccountReceivables | 0.00 | 127.97K | 21.12K | 57.65K |
| OtherNonCashItems | 4.89M | 143.00 | 24.41K | 30.53K |
| StockBasedCompensation | 415.23K | 1.22M | 1.05M | 750.62K |
| DepreciationAmortizationDepletion | 339.56K | 359.06K | 240.89K | 123.69K |
| DepreciationAndAmortization | 339.56K | 359.06K | 240.89K | 123.69K |
| AmortizationCashFlow | 550.00 | 550.00 | 550.00 | |
| AmortizationOfIntangibles | 550.00 | 550.00 | 550.00 | |
| Depreciation | 339.01K | 358.51K | 240.34K | |
| OperatingGainsLosses | 21.14K | 142.12K | ||
| GainLossOnSaleOfPPE | 0.00 | 21.14K | 0.00 | |
| GainLossOnSaleOfBusiness | 0.00 | 142.12K | 0.00 | |
| NetIncomeFromContinuingOperations | -13.39M | -12.21M | -12.03M | -10.42M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AEMD
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|